NRX Pharmaceuticals Warrant
NRXPW
NRXPW was delisted on the 22nd of May, 2026.
2 hedge funds and large institutions have $347 invested in NRX Pharmaceuticals Warrant in 2026 Q1 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
6.58% more ownership
Funds ownership: 0% → 6.58% (+6.6%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
33% less funds holding
Funds holding: 3 → 2 (-1)
85% less capital invested
Capital invested by funds: $2.38K → $347 (-$2.03K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
+$56 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$669 |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$80 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
WAM
1
Wolverine Asset Management
Chicago,
Illinois
| $347 | +$56 | +1,300 | +6% |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$669 | -11,412 | Closed |
|
|
3
UBS Group
Zurich,
Switzerland
| – | -$80 | -1,839 | -99% |
|
NRXPW Hedge Fund Activity: Q1 2026 in Review
2 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in NRX Pharmaceuticals Warrant (NRXPW) for Q1 2026, worth a combined $347 — down 85% from $2.38K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of NRXPW and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 1 added.
The largest buyer was Wolverine Asset Management, adding an estimated $56. The largest seller was Susquehanna International Group, exiting entirely with an estimated $669 sold.
- 2 institutional investors held NRX Pharmaceuticals Warrant (NRXPW) as of Q1 2026, down from 3 in Q4 2025.
- Funds reported $347 of NRX Pharmaceuticals Warrant stock for Q1 2026, down 85% quarter-over-quarter.
- 0 funds opened new NRX Pharmaceuticals Warrant positions in Q1 2026 and 1 closed out, a net change of -1 holder.
- The largest NRX Pharmaceuticals Warrant buyer in Q1 2026 was Wolverine Asset Management, an estimated $56 added.
- The largest NRX Pharmaceuticals Warrant seller in Q1 2026 was Susquehanna International Group, an estimated $669 sold.
Based on aggregated 13F filings for Q1 2026.